General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 91: What is the branch that deals with medicinal drugs obtained from plants and other natural resources?

A. Pharmacognosy (Correct Answer)
B. Pharmacogenetics
C. Pharmacogenomics
D. Pharmacopeia

Explanation: ### Explanation **Correct Answer: A. Pharmacognosy** **Pharmacognosy** is the branch of pharmacology that deals with the study of crude drugs derived from natural sources, such as plants, animals, and minerals. The term is derived from the Greek words *pharmakon* (drug) and *gnosis* (knowledge). It involves the identification, physicochemical characterization, and cultivation of natural medicinal substances (e.g., Morphine from *Papaver somniferum*, Digoxin from *Digitalis lanata*). **Analysis of Incorrect Options:** * **B. Pharmacogenetics:** This is the study of how a **single gene** influences an individual’s response to a specific drug (e.g., G6PD deficiency causing hemolysis with Primaquine). * **C. Pharmacogenomics:** A broader term than pharmacogenetics, it involves the study of how the **entire genome** (multiple genes) affects drug response and toxicity, aiming for "personalized medicine." * **D. Pharmacopeia:** This is an **official publication** (legal record) containing a list of medicinal drugs with their effects and directions for use, published by a recognized authority (e.g., IP, BP, USP). **High-Yield Clinical Pearls for NEET-PG:** * **Father of Pharmacology:** Oswald Schmiedeberg. * **Father of Indian Pharmacology:** Ram Nath Chopra. * **Pharmacokinetics:** What the **body does to the drug** (ADME: Absorption, Distribution, Metabolism, Excretion). * **Pharmacodynamics:** What the **drug does to the body** (Mechanism of action and pharmacological effects). * **Therapeutics:** The application of pharmacological information together with the knowledge of the disease for its prevention and cure.

Question 92: What is the mechanism of action of cyclosporine?

A. Inhibits IL-2 receptors
B. Inhibits TNF alpha
C. Decreases transcription of the IL-2 gene (Correct Answer)
D. Targets inactivated T cells

Explanation: **Mechanism of Action: Cyclosporine** **Correct Answer: C. Decreases transcription of the IL-2 gene** **Explanation:** Cyclosporine is a potent immunosuppressant belonging to the **calcineurin inhibitor** class. Its mechanism involves several steps: 1. Cyclosporine enters the T-cell and binds to a specific cytoplasmic receptor protein called **Cyclophilin**. 2. The Cyclosporine-Cyclophilin complex binds to and inhibits **Calcineurin**, a phosphatase enzyme. 3. Under normal conditions, calcineurin dephosphorylates **NFAT** (Nuclear Factor of Activated T-cells), allowing it to enter the nucleus. 4. By inhibiting calcineurin, cyclosporine prevents the dephosphorylation and nuclear translocation of NFAT. 5. Consequently, there is a failure to activate the promoter region of the **Interleukin-2 (IL-2) gene**, leading to **decreased transcription** and production of IL-2. Since IL-2 is the primary driver for T-cell proliferation, the immune response is suppressed. **Why other options are incorrect:** * **Option A:** Drugs like **Basiliximab** and **Daclizumab** are monoclonal antibodies that specifically block the IL-2 receptor (CD25). * **Option B:** TNF-alpha inhibitors include drugs like **Etanercept, Infliximab, and Adalimumab**, used primarily in Rheumatoid Arthritis and IBD. * **Option D:** Cyclosporine targets **activated** T-cells (specifically the G0 or G1 phase). It does not target inactivated cells. **High-Yield NEET-PG Pearls:** * **Side Effects:** Nephrotoxicity (most common/serious), Gingival Hyperplasia, Hirsutism, and Hypertension. * **Metabolism:** Metabolized by **CYP3A4**; avoid grapefruit juice as it increases drug levels. * **Clinical Use:** Organ transplantation (prophylaxis of graft rejection) and autoimmune disorders like Psoriasis and Uveitis. * **Comparison:** **Tacrolimus** has a similar mechanism but binds to **FK-Binding Protein (FKBP-12)** instead of cyclophilin.

Question 93: What is the mechanism of action of dantrolene?

A. Inhibits Ca++ secretion from sarcoplasm
B. Binds to ryanodine receptors to block the release of Ca++ (Correct Answer)
C. Inhibits GABA
D. Inhibits the gamma motor neuron

Explanation: **Explanation:** **Mechanism of Action:** Dantrolene is a direct-acting skeletal muscle relaxant. Its primary mechanism involves binding to the **Ryanodine Receptor 1 (RyR1)** located on the membrane of the **sarcoplasmic reticulum** (SR) in skeletal muscle cells [1]. By antagonizing these receptors, dantrolene inhibits the release of stored calcium ions ($Ca^{2+}$) into the cytosol. Since intracellular calcium is essential for excitation-contraction coupling, its reduction prevents muscle fiber contraction without affecting neuromuscular transmission or cardiac/smooth muscle (which utilize different RyR isoforms) [1]. **Analysis of Options:** * **Option A:** While dantrolene does reduce calcium levels in the sarcoplasm, it specifically inhibits the **release** from the SR, not "secretion" (a term usually reserved for glandular activity). * **Option C:** GABA is the primary inhibitory neurotransmitter in the CNS [1]. Drugs like benzodiazepines or baclofen act via GABA receptors, but dantrolene acts peripherally on the muscle itself [1]. * **Option D:** Inhibition of gamma motor neurons is the mechanism associated with centrally acting muscle relaxants (e.g., diazepam), not direct-acting agents like dantrolene. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** Dantrolene is the life-saving treatment for **Malignant Hyperthermia** (often triggered by succinylcholine or halothane) and **Neuroleptic Malignant Syndrome (NMS)**. * **Other Uses:** Management of spasticity associated with Upper Motor Neuron lesions (e.g., Cerebral Palsy, Multiple Sclerosis). * **Side Effect:** The most significant adverse effect is **hepatotoxicity** (monitor liver function tests). * **Key Distinction:** Unlike non-depolarizing blockers (e.g., vecuronium), dantrolene does not act at the nicotinic acetylcholine receptor (nAChR).

Question 94: What is the primary purpose of an orphan drug?

A. To treat common conditions with the expectation of significant profit for the manufacturer.
B. To treat rare conditions with the expectation of significant profit for the manufacturer.
C. To treat rare conditions with no expectation of significant profit for the manufacturer. (Correct Answer)
D. None of the above.

Explanation: ### Explanation **Orphan drugs** are biological products or medicines intended for the diagnosis, prevention, or treatment of **rare diseases** (e.g., Gaucher’s disease, Cystic Fibrosis, or Leprosy). The term "orphan" reflects the fact that these drugs are commercially unattractive to the pharmaceutical industry. Because the patient population is so small, the cost of research, development, and marketing cannot be recovered through sales. Therefore, they are developed with **no expectation of significant profit**, requiring government incentives (like the Orphan Drug Act) to encourage production. **Analysis of Options:** * **Option A is incorrect:** Drugs for common conditions (like hypertension or diabetes) are "blockbuster drugs," not orphan drugs, as they target large populations and generate high revenue. * **Option B is incorrect:** While the target is rare conditions, the lack of profit potential is a defining characteristic of an orphan drug. If a drug for a rare disease were highly profitable without incentives, it wouldn't fit the traditional "orphan" status. * **Option C is correct:** It accurately identifies both the target (rare diseases) and the economic reality (low profitability). **NEET-PG High-Yield Pearls:** * **Definition of Rare Disease:** In the US, it is a condition affecting <200,000 people; in India, it generally refers to conditions with a prevalence of <1 in 2,500. * **Examples of Orphan Drugs:** **Digoxin immune Fab** (Digibind), **Liothyronine** (T3), **Fomepizole** (for methanol poisoning), and **Amphotericin B** (for Leishmaniasis). * **Incentives:** Governments provide tax credits, simplified marketing authorization, and extended **patent exclusivity** (usually 7 years) to make development viable.

Question 95: All of the following are true about gantacurium, except:

A. Its onset and duration are similar to succinylcholine.
B. It is a nondepolarizing neuromuscular blocker.
C. It is not metabolized by pseudocholinesterase.
D. It is a benzylisoquinoline nondepolarizing neuromuscular blocker. (Correct Answer)

Explanation: **Explanation:** Gantacurium is an ultra-short-acting **chlorofumarate** neuromuscular blocker currently under investigation. It was designed to provide a non-depolarizing alternative to succinylcholine. **1. Why Option D is the "Except" (Correct Answer):** While gantacurium is structurally related to the **benzylisoquinoline** class (like atracurium), it is technically classified as a **chlorofumarate** derivative. In the context of this specific question, the distinction lies in its unique metabolism. Unlike typical benzylisoquinolines, it undergoes rapid degradation via **cysteine conjugation** (a non-enzymatic process) and ester hydrolysis, rather than Hofmann elimination. **2. Analysis of Other Options:** * **Option A:** Gantacurium has an exceptionally rapid onset (1–2 minutes) and a very short duration of action (recovery in ~10 minutes), making its profile very similar to **succinylcholine**, but without the side effects of depolarization. * **Option B:** It is a **non-depolarizing** agent. It acts as a competitive antagonist at the nicotinic acetylcholine receptors (Nm) at the neuromuscular junction. * **Option C:** It is **not metabolized by pseudocholinesterase** (butyrylcholinesterase). This is a significant advantage over succinylcholine, as it can be safely used in patients with pseudocholinesterase deficiency. **High-Yield Clinical Pearls for NEET-PG:** * **Metabolism:** Primarily inactivated by rapid non-enzymatic **cysteine conjugation**. * **Reversal:** Its effects can be rapidly reversed by the administration of **L-cysteine**, which accelerates its degradation. * **Side Effects:** Like other benzylisoquinoline-related compounds, rapid bolus doses may cause **histamine release**, leading to transient hypotension or flushing. * **Clinical Utility:** Intended for rapid sequence intubation (RSI) where a short duration of action is desired.

Question 96: Which of the following is a common cause of electrolyte abnormalities?

A. Potassium Chloride (KCl)
B. 0.9% Sodium Chloride (NaCl)
C. Sodium Bicarbonate (NaHCO3)
D. Aluminum Hydroxide (Al(OH)3) (Correct Answer)

Explanation: **Explanation:** The correct answer is **Aluminum Hydroxide [Al(OH)3]**. While it is primarily used as an antacid, its clinical significance in pharmacology often relates to its role as a **phosphate binder**. **1. Why Aluminum Hydroxide is the correct answer:** Aluminum hydroxide reacts with hydrochloric acid in the stomach to form aluminum chloride and water. In the small intestine, aluminum ions bind to dietary phosphate to form insoluble aluminum phosphate, which is excreted in the feces. This prevents phosphate absorption, leading to **Hypophosphatemia** (low serum phosphate). Chronic use can lead to osteomalacia and proximal muscle weakness due to depleted phosphate levels. **2. Analysis of Incorrect Options:** * **Potassium Chloride (KCl):** This is a supplement used to *treat* hypokalemia. While an overdose can cause hyperkalemia, it is administered specifically to maintain or restore electrolyte balance, not typically cited as a "common cause" of spontaneous abnormality in a general pharmacological context. * **0.9% Sodium Chloride (NaCl):** Known as Normal Saline, it is isotonic. While large volumes can cause hyperchloremic metabolic acidosis, it is the standard fluid for resuscitation and does not inherently cause electrolyte "abnormalities" when used appropriately. * **Sodium Bicarbonate (NaHCO3):** Used to treat metabolic acidosis and alkalinize urine. While it can lead to metabolic alkalosis or hypernatremia in excess, it is a therapeutic agent for correcting imbalances rather than a primary causative agent for electrolyte depletion. **3. NEET-PG High-Yield Pearls:** * **Antacid Side Effects:** Remember the mnemonic **"AC/BD"**—**A**luminum causes **C**onstipation; **M**agnesium causes **D**iarrhea. * **Phosphate Binding:** Aluminum hydroxide is used therapeutically in Chronic Kidney Disease (CKD) to manage hyperphosphatemia, but its long-term use is limited due to aluminum toxicity (dialysis encephalopathy). * **Milk-Alkali Syndrome:** Characterized by the triad of hypercalcemia, metabolic alkalosis, and renal failure, often due to excessive calcium carbonate ingestion.

Question 97: Which of the following is NOT a prodrug?

A. Levodopa
B. Lisinopril (Correct Answer)
C. Carbimazole
D. Prednisolone

Explanation: **Explanation:** A **prodrug** is a pharmacologically inactive compound that must undergo metabolic conversion (usually in the liver) to become an active metabolite. **Why Lisinopril is the correct answer:** Most ACE inhibitors are prodrugs (e.g., Enalapril converts to Enalaprilat) to improve oral bioavailability. However, **Lisinopril** and **Captopril** are the two major exceptions; they are active drugs themselves and do not require hepatic activation. This makes them preferred in patients with liver dysfunction. **Analysis of Incorrect Options:** * **Levodopa:** It is the metabolic precursor of **Dopamine**. Since dopamine cannot cross the blood-brain barrier, Levodopa is administered and then converted to active dopamine in the CNS by the enzyme DOPA decarboxylase. * **Carbimazole:** This antithyroid drug is a prodrug that is rapidly converted to its active form, **Methimazole**, which inhibits the synthesis of thyroid hormones. * **Prednisolone:** While **Prednisone** is a prodrug (converted to Prednisolone in the liver), **Prednisolone** itself is the active metabolite. *Note: In some contexts, Prednisolone is considered active, but it can further convert to other metabolites; however, compared to the other options, it is frequently tested as the active form vs. Prednisone.* **High-Yield Clinical Pearls for NEET-PG:** * **ACE Inhibitor Mnemonic:** All ACE inhibitors are prodrugs **EXCEPT** Captopril and Lisinopril. * **Common Prodrugs to Remember:** Enalapril, Ramipril, Valacyclovir (to Acyclovir), Clopidogrel, Cyclophosphamide, and Sulfasalazine. * **Advantage of Prodrugs:** They often have better absorption, reduced side effects at the site of administration, or a longer duration of action.

Question 98: Allergic reactions depend on all except:

A. Previous exposure to the drug
B. Dosage of the drug received (Correct Answer)
C. Pharmacological action of the drug
D. Antigen-antibody reaction

Explanation: ### Explanation Drug allergy (hypersensitivity) is an **immunologically mediated** reaction that is distinct from the drug's known pharmacological effects. **Why "Dosage of the drug received" is the correct answer:** Unlike side effects or toxicities, allergic reactions are **not dose-dependent**. Even a minute, sub-therapeutic dose (e.g., a skin prick test) can trigger a life-threatening anaphylactic response in a sensitized individual. The severity of the reaction is determined by the individual's immune sensitivity rather than the amount of drug administered. **Analysis of Incorrect Options:** * **Previous exposure to the drug:** This is a hallmark of Type I, II, and III hypersensitivity. The immune system must first be "sensitized" by a prior exposure to produce specific antibodies or sensitized T-cells. * **Pharmacological action of the drug:** Allergic reactions are independent of the drug's intended mechanism. For example, the allergic rash caused by Penicillin has nothing to do with its ability to inhibit bacterial cell wall synthesis. * **Antigen-antibody reaction:** Most drug allergies (Types I, II, and III) involve the interaction between the drug (acting as a hapten) and antibodies (IgE, IgG, or IgM). Type IV involves T-cell mediation, but the underlying principle remains an immune-antigen recognition. **High-Yield Clinical Pearls for NEET-PG:** * **Haptens:** Most drugs are small molecules (<1000 Da) and are not immunogenic alone. They become antigenic only after binding to endogenous proteins; these are called haptens. * **Gell and Coombs Classification:** * **Type I:** Immediate/Anaphylactic (IgE mediated). * **Type II:** Cytotoxic (IgG/IgM). * **Type III:** Immune-complex (Serum sickness). * **Type IV:** Delayed hypersensitivity (T-cell mediated; e.g., Contact dermatitis). * **Predictability:** Allergic reactions are **unpredictable** and occur only in a small percentage of the population (idiosyncratic/immunologic).

Question 99: According to the two-state receptor theory, which of the following statements BEST explains the term "agonists"?

A. Strong affinity for the receptor in the active state (Ra) (Correct Answer)
B. Strong affinity for the receptor in the inactive state (Ri)
C. Equal affinity for Ra and Ri
D. Slightly more affinity for Ra than Ri

Explanation: ### Explanation The **Two-State Receptor Model** (or Ternary Complex Model) proposes that receptors exist in a reversible equilibrium between two conformational states: **Inactive ($R_i$)** and **Active ($R_a$)**. Even in the absence of a drug, some receptors spontaneously transition to the $R_a$ state, leading to "constitutive activity." #### Why Option A is Correct: An **Agonist** has a high and selective affinity for the **Active state ($R_a$)**. By binding preferentially to $R_a$, the agonist shifts the equilibrium toward the active conformation. This results in a maximal biological response. #### Analysis of Incorrect Options: * **Option B (Strong affinity for $R_i$):** This describes an **Inverse Agonist**. By stabilizing the inactive state, inverse agonists reduce the constitutive activity of the receptor (e.g., Beta-carbolines at GABA receptors). * **Option C (Equal affinity for $R_a$ and $R_i$):** This describes a **Competitive Antagonist**. Because it binds equally to both states, it does not shift the equilibrium; it merely prevents agonists from binding. * **Option D (Slightly more affinity for $R_a$ than $R_i$):** This describes a **Partial Agonist**. It has a higher affinity for $R_a$ than $R_i$, but not to the same degree as a full agonist, resulting in a sub-maximal response even at 100% receptor occupancy. --- ### High-Yield Clinical Pearls for NEET-PG * **Constitutive Activity:** The baseline signaling occurring without any ligand. Receptors for GABA, Histamine, and Opioids often show high constitutive activity. * **Intrinsic Activity ($\alpha$):** * Full Agonist: $\alpha = 1$ * Antagonist: $\alpha = 0$ * Partial Agonist: $\alpha$ is between 0 and 1 * Inverse Agonist: $\alpha$ is negative (usually -1) * **Key Example:** Propranolol is technically an **inverse agonist** at $\beta$-receptors, not just a simple antagonist, as it reduces the resting heart rate by shifting receptors to the $R_i$ state.

Question 100: What is the concentration of Potassium in Ringer's Lactate solution?

A. 1 mEq/L
B. 4 mEq/L (Correct Answer)
C. 2 mEq/L
D. 6 mEq/L

Explanation: **Explanation:** Ringer's Lactate (RL), also known as Hartmann's solution, is a balanced crystalloid solution designed to closely mimic the electrolyte composition of human plasma. It is the fluid of choice for resuscitation in burns and hemorrhagic shock. **1. Why Option B is Correct:** The concentration of **Potassium (K+) in Ringer's Lactate is 4 mEq/L**. This concentration is intentionally set to reflect the normal physiological range of potassium in human extracellular fluid (3.5–5.0 mEq/L). Because it contains potassium, RL must be used with caution in patients with renal failure or hyperkalemia. **2. Why Other Options are Incorrect:** * **Options A and C (1 & 2 mEq/L):** These concentrations are too low to maintain physiological homeostasis in a balanced salt solution. * **Option D (6 mEq/L):** This exceeds the normal physiological limit of plasma potassium. Infusing a solution with 6 mEq/L as a primary maintenance or resuscitation fluid could inadvertently induce iatrogenic hyperkalemia. **3. High-Yield Clinical Pearls for NEET-PG:** * **Composition of RL (per Liter):** * Sodium (Na+): 130–131 mEq/L (Hypotonic compared to Normal Saline) * Chloride (Cl-): 109–111 mEq/L * Lactate: 28 mEq/L (Converted to bicarbonate in the liver; useful in metabolic acidosis) * Calcium (Ca2+): 3 mEq/L * **Contraindication:** Do not co-administer RL with blood transfusions in the same IV line. The **Calcium** in RL can bind to the **Citrate** anticoagulant in stored blood, leading to clot formation. * **Metabolic Note:** RL is contraindicated in patients with severe liver disease because they cannot metabolize lactate into bicarbonate, potentially worsening lactic acidosis.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free